Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Blog
Blog Library
Machine Learning and Intelligent Forecasting: Beyond the Black Box
The black box. That mysterious widget in which myriad magic tricks reside. For some it is a magical force that delivers exactly what you need, even if you don’t entirely…
What to expect from JP Morgan 2023
The real start to the biopharma year, the JP Morgan Healthcare Conference, is nearly upon us. As the holidays fade into memory – along with a pretty rough 2022 – what…
Meet the Evaluate Team: Ulyssa MacMillan
Evaluate is awash with team members who ensure our products are best in class, while also being splendid people to have around. In our latest edition of the Meet the Team…
What is Intelligent Forecasting?
Intelligent forecasting is a hugely powerful tool for the life sciences industry...but what exactly IS it?
Meet the Evaluate Team: Andreas Hadjivasiliou
Behind Evaluate’s data and insights about the biopharma space, there are people who work to make sure that our clients have the data and insight they need to make the…
Upcoming catalysts, a New Year’s celebration for some
Got 10 minutes? Grab a coffee and listen to our latest podcast looking at the latest and upcoming readouts to see what's going to be hot as we head into 2023.
Evaluating the London Marathon
Running a marathon is never easy, but the right motivation (and peanut butter) certainly help.
Meet the Evaluate Team: Christina Kay
Behind Evaluate’s data and insights about the biopharma space, there are people who work to make sure that our clients have everything they need to make their lives a…
Meet the Evaluate Team: Cem Baydar
Evaluate may be a business founded on great data and insights, but it’s the people that make the magic happen. In this new blog series, we’ll introduce the people behind…
Medtech in 2028: Suffering or celebrating a Covid hangover?
We've extended our forecasts out to 2028 and in our latest report, we take a look at what's in store for the medtech market in the next few years.